Clinical Research Directory
Browse clinical research sites, groups, and studies.
PATH Trial: Personalized Approaches in the Treatment of Head and Neck Cancer
Sponsor: British Columbia Cancer Agency
Summary
1. To determine genomic markers of radioresistance by comparing patients with H\&N cancer who develop recurrence within twelve months of curative intent radiation and/or chemoradiotherapy to those without recurrence 2. To compare the genomic landscape of patients with and without EBV and HPV mediated H\&N cancer 3. To identify somatic mutations, gene expression changes or other potentially targetable abnormalities in patients with recurrent H\&N cancer that may provide information to guide systemic therapy in these patients
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2022-08
Completion Date
2032-08
Last Updated
2022-05-13
Healthy Volunteers
No
Conditions
Interventions
Whole genomic DNA/RNA tumour sequencing
All participants will undergo pre-radiotherapy fresh core biopsies of the tumour. DNA libraries will be created and stored for future analysis. Participants with recurrence will have biopsy and subsequently will undergo rapid sequencing of RNA and DNA followed by bioinformatic analysis to identify somatic mutations or other abnormalities that might be "drivers" of an individual's cancer or predict response to therapies. These data will be compared to the literature and to a comprehensive database of drugs with the aim of identifying drugs most likely to target individual tumors based on the presence of mutated or abnormally expressed genes in the tumor. Any palliative systemic therapy treatment would be closely monitored for tolerability and response, as part of the general clinical care of someone on systemic therapy. The choice of systemic therapy will be up to the treating medical oncologist and the patient.